RxDoctor Payments Data

Ronald Kane, MD

Family Medicine · Scottsdale, AZNPI 1114941994

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 5 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 5 manufacturers reported payments, led by Shionogi Inc at 40.9% of the total. 2025 is the largest year on record at $240, more than ten times the $13 reported in 2019. That places this record below the midpoint for family medicine clinicians in AZ, where the typical reported total is $231.

$296in general payments, 2019–2025

Across 5 payments — averaging $59.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Shionogi Inc$121
  • AbbVie$120
  • Otsuka America Pharmaceutical, Inc.$27
  • Lilly USA, LLC$15
  • Osiris Therapeutics Inc.$13

What the payments were for

  • Food & beverage$296100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$296 in reported general payments places this provider in the 50th percentile of 2,099 family medicine providers in Arizona.

See all family medicine providers in Arizona →

Medicare billing

Part B allowed, 2024
$270,895
Medicare patients
303
Services billed
3,087

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban252$80,625
MounjaroTirzepatide11$12,292
Combivent RespimatIpratropium/Albuterol Sulfate20$10,983
MyrbetriqMirabegron29$7,348
LinzessLinaclotide11$6,265
EntrestoSacubitril/Valsartan17$5,808
JanuviaSitagliptin Phosphate20$5,577
Atorvastatin Calcium262$5,109
Incruse ElliptaUmeclidinium Bromide44$4,633
Pantoprazole Sodium101$4,516
Gabapentin178$4,127
Trelegy ElliptaFluticasone/Umeclidin/Vilanter12$3,916
Wixela InhubFluticasone Propion/Salmeterol33$3,886
Potassium Chloride89$3,316
BelsomraSuvorexant16$2,968

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$15$12,29211 claims
AbbVieLinzess$120$6,26511 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 2,099 family medicine providers in Arizona.

Other family medicine in Scottsdale

See the full list for Arizona →

Where these figures come from

Is this you, or does something look wrong? →